Being the CD8+ CTLs the final effectors of the adaptive anti-tumor immune response, it is expected that the expression of MHC-I molecules in tumor cells represents one of the most important parameters associated with the efficacy of the immune response itself. This evidence concerns the gene CD8A and neoplasm.